AVIR vs. NKTX, VTYX, VRCA, KMDA, SBTX, ORGO, ATAI, PGEN, CRMD, and NLTX
Should you be buying Atea Pharmaceuticals stock or one of its competitors? The main competitors of Atea Pharmaceuticals include Nkarta (NKTX), Ventyx Biosciences (VTYX), Verrica Pharmaceuticals (VRCA), Kamada (KMDA), Silverback Therapeutics (SBTX), Organogenesis (ORGO), Atai Life Sciences (ATAI), Precigen (PGEN), CorMedix (CRMD), and Neoleukin Therapeutics (NLTX). These companies are all part of the "pharmaceutical preparations" industry.
Nkarta (NASDAQ:NKTX) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.
Nkarta's return on equity of -29.18% beat Atea Pharmaceuticals' return on equity.
80.5% of Nkarta shares are owned by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 5.6% of Nkarta shares are owned by insiders. Comparatively, 14.5% of Atea Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Nkarta has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500. Comparatively, Atea Pharmaceuticals has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500.
Nkarta has higher earnings, but lower revenue than Atea Pharmaceuticals. Nkarta is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Atea Pharmaceuticals had 16 more articles in the media than Nkarta. MarketBeat recorded 23 mentions for Atea Pharmaceuticals and 7 mentions for Nkarta. Nkarta's average media sentiment score of 0.13 beat Atea Pharmaceuticals' score of 0.11 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media.
Nkarta received 31 more outperform votes than Atea Pharmaceuticals when rated by MarketBeat users. Likewise, 72.73% of users gave Nkarta an outperform vote while only 47.22% of users gave Atea Pharmaceuticals an outperform vote.
Nkarta presently has a consensus price target of $17.83, indicating a potential upside of 173.10%. Given Atea Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Nkarta is more favorable than Atea Pharmaceuticals.
Summary
Nkarta and Atea Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.
Get Atea Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Atea Pharmaceuticals Competitors List
Related Companies and Tools
